RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
Status:
RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This phase I/II tests the safety, side effects, best dose and how well giving RYZ101 works for the treatment of patients with intracranial meningioma that is growing, spreading, or getting worse (progressive) or that has come back after a period of improvement (recurrent). RYZ101 is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving RYZ101 may be safe, tolerable and/or effective in treating patients with progressive or recurrent intracranial meningioma.
Phase:
PHASE1
Details
Lead Sponsor:
Joshua Palmer
Collaborator:
RayzeBio, Inc.
Treatments:
Arginine Ga(III)-DOTATOC gallium Ga 68 dotatate Lysine Magnetic Resonance Spectroscopy Specimen Handling